We are expanding our research tool offerings to include Patient–Derived Xenograft (PDX) models. Coming soon, we have a collection of breast cancer PDX models developed from patients affected by the most advanced and lethal forms of breast cancer, such as aggressive, metastatic and treatment–resistant subtypes. Further ahead; we are looking forward to adding a collection of Non-Small Cell Lung Cancer (NSCLC) models.
PDX models are generated by grafting tumour tissues from a patient into immunodeficient mice. Allowing for a superior recapitulation of the key characteristics of cancers, including spatial structure and intra-tumour heterogeneity, while maintaining the patients’ genomic features. As a result, PDX models are a mainstay in preclinical cancer research.
These PDX models offer an ideal translational system to test therapy efficacy, especially in metastasis. Traditional preclinical models often fail to accurately represent the complex nature of metastatic disease, making PDX models a superior choice for studying advanced cancers.
